Lipid Profile, Renal Function Tests and Inflammatory Markers in Algerian Type 2 Diabetic Patients

Overview

Journal Iran J Public Health

Date 2023 Aug 8

PMID 37551187

Authors

Mohammed Hadjari

Karima Bereksi

Affiliations

Soon will be listed here.

Abstract

Background: Several studies show the relationship between chronic hyperglycemia and the appearance of macroangiopathy, microangiopathy and neuropathy. The major objective of this study was to investigate the serum lipids, renal function tests and inflammatory markersin type 2 diabetes patients.

Methods: The study lasted eight years between Feb-2013 and Mar-2021 (Mascara, Algeria). Overall,197 patients and 197 controls were selected during general medicine examinations; enzymatic and immunoturbidimetric colorimetric methods were used to determine the serum levels offasting glycaemia, total cholesterol, highdensity lipoprotein cholesterol, triglycerides, low-density lipoprotein cholesterol, fibrinogen, urea, acid uric, albumin and creatinine, C protein reactive; the glomerular filtration rate is calculated according to the MDRD equation; the glycatedhaemoglobin levels were determined by an ion-exchange resin separation method.

Results: Patients had 2.44 times higher fasting glycaemia, 1.71 times higher HbA1c, 1.23 times higher body mass index, 1.30 times higher waist circumference and 1.25times higher systolic blood pressure than control subjects; the findings of the present study also indicate that a significant differences between patients and controls were observed regarding triglycerides (=0.008), LDL-cholesterol (=0.011), HDL-cholesterol (=0.009), urea (=0.013), uric acid (=0.015), creatinine (=0.007), glomerular filtration rate (=0.006), albumin (=0.018), fibrinogen (=0.023) and C protein reactive (=0.019).

Conclusion: All this metabolic disordercould facilitate the appearance of serious complications in future.

References

Schofield J, Liu Y, Rao-Balakrishna P, Malik R, Soran H . Diabetes Dyslipidemia. Diabetes Ther. 2016; 7(2):203-19. PMC: 4900977. DOI: 10.1007/s13300-016-0167-x. View

Zhang J, Wang Y, Zhang R, Li H, Han Q, Wu Y . Serum fibrinogen predicts diabetic ESRD in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018; 141:1-9. DOI: 10.1016/j.diabres.2018.04.025. View

Dunkler D, Kohl M, Heinze G, Teo K, Rosengren A, Pogue J . Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. Kidney Int. 2014; 87(4):784-91. DOI: 10.1038/ki.2014.370. View

Gagliardi A, Miname M, Santos R . Uric acid: A marker of increased cardiovascular risk. Atherosclerosis. 2008; 202(1):11-7. DOI: 10.1016/j.atherosclerosis.2008.05.022. View

Thorn L, Forsblom C, Fagerudd J, Thomas M, Pettersson-Fernholm K, Saraheimo M . Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care. 2005; 28(8):2019-24. DOI: 10.2337/diacare.28.8.2019. View

Jin J, Zhang H, Cao Y, Liu H, Hua Q, Li Y . Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study. Cardiovasc Diabetol. 2020; 19(1):45. PMC: 7118853. DOI: 10.1186/s12933-020-01015-6. View

Chen M, Shi W, Wang H, Li Z, Guo X, Sun Y . Interaction of General or Central Obesity and Hypertension on Diabetes: Sex-Specific Differences in a Rural Population in Northeast China. Diabetes Metab Syndr Obes. 2021; 14:1061-1072. PMC: 7955680. DOI: 10.2147/DMSO.S295960. View

Ebrahimi M, Heidari-Bakavoli A, Shoeibi S, Mirhafez S, Moohebati M, Esmaily H . Association of Serum hs-CRP Levels With the Presence of Obesity, Diabetes Mellitus, and Other Cardiovascular Risk Factors. J Clin Lab Anal. 2016; 30(5):672-6. PMC: 6807047. DOI: 10.1002/jcla.21920. View

Gonzalez-Baro M, Lewin T, Coleman R . Regulation of Triglyceride Metabolism. II. Function of mitochondrial GPAT1 in the regulation of triacylglycerol biosynthesis and insulin action. Am J Physiol Gastrointest Liver Physiol. 2006; 292(5):G1195-9. PMC: 2819211. DOI: 10.1152/ajpgi.00553.2006. View

10.

Kanwar Y, Wada J, Sun L, Xie P, Wallner E, Chen S . Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood). 2007; 233(1):4-11. DOI: 10.3181/0705-MR-134. View

11.

Schneider D . Abnormalities of coagulation, platelet function, and fibrinolysis associated with syndromes of insulin resistance. Coron Artery Dis. 2005; 16(8):473-6. DOI: 10.1097/00019501-200512000-00003. View

12.

Staplin N, Haynes R, Herrington W, Reith C, Cass A, Fellstrom B . Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). Am J Kidney Dis. 2016; 68(3):371-80. PMC: 4996629. DOI: 10.1053/j.ajkd.2016.02.052. View

13.

Betteridge D . Lipid control in patients with diabetes mellitus. Nat Rev Cardiol. 2011; 8(5):278-90. DOI: 10.1038/nrcardio.2011.23. View

14.

Kikkawa K, Nakajima K, Shimomura Y, Tokita Y, Machida T, Sumino H . Small dense LDL cholesterol measured by homogeneous assay in Japanese healthy controls, metabolic syndrome and diabetes patients with or without a fatty liver. Clin Chim Acta. 2014; 438:70-9. DOI: 10.1016/j.cca.2014.07.017. View

15.

Chehade J, Gladysz M, Mooradian A . Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013; 73(4):327-39. DOI: 10.1007/s40265-013-0023-5. View

16.

Akhtar D, Iqbal U, Vazquez-Montesino L, Dennis B, Ahmed A . Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2020; 7(4):362-370. PMC: 6943204. DOI: 10.14218/JCTH.2019.00028. View

17.

Ting M, Liao P, Wu I, Chen S, Yang N, Lin T . Predicting Type 2 Diabetes Mellitus Occurrence Using Three-Dimensional Anthropometric Body Surface Scanning Measurements: A Prospective Cohort Study. J Diabetes Res. 2018; 2018:6742384. PMC: 6079414. DOI: 10.1155/2018/6742384. View

18.

Gross J, de Azevedo M, Silveiro S, Canani L, Caramori M, Zelmanovitz T . Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2004; 28(1):164-76. DOI: 10.2337/diacare.28.1.164. View

19.

Ang L, Palakodeti V, Khalid A, Tsimikas S, Idrees Z, Tran P . Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol. 2008; 52(13):1052-9. DOI: 10.1016/j.jacc.2008.05.054. View

20.

Alloubani A, Saleh A, Abdelhafiz I . Hypertension and diabetes mellitus as a predictive risk factors for stroke. Diabetes Metab Syndr. 2018; 12(4):577-584. DOI: 10.1016/j.dsx.2018.03.009. View